Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Zopiclone
Drug ID BADD_D02397
Description Zopiclone is a novel hypnotic agent used in the treatment of insomnia. Its mechanism of action is based on modulating benzodiazepine receptors. In addition to zopiclone's benzodiazepine pharmacological properties it also has some barbiturate-like properties.
Indications and Usage For the short-term treatment of insomnia.
Marketing Status approved
ATC Code N05CF01
DrugBank ID DB01198
KEGG ID D01372
MeSH ID C515050
PubChem ID 5735
TTD Drug ID D0ZB7K
NDC Product Code 66639-265; 64330-058; 63190-0030; 65372-1185
UNII 03A5ORL08Q
Synonyms zopiclone | 6-(5-chloro-2-pyridyl)-6,7-dihydro- 7-oxo-5H-pyrrolo(3,4-b)pyrazin-5-yl 4-methyl-1- piperazinecarboxylate | Zop | Zopicalma | zopiclodura | Zopiclon AbZ | Zopiclon AL | Zopiclon AZU | Zopiclon beta | Zopiclon Stada | Zopiclon TAD | zopiclon von ct | Zopiclon-neuraxpharm | Zopiclon-TEVA | Zopitan | Zorclone | Imovane | Ximovan | Zimovane | Limovan | Nu-Zopiclone | Optidorm | ratio-Zopiclone | Zopiclon-ratiopharm | Rhovane | RP 27 267 | Siaten | Somnosan | Zileze | Zimoclone | Zopi-Puren | Zopicalm
Chemical Information
Molecular Formula C17H17ClN6O3
CAS Registry Number 43200-80-2
SMILES CN1CCN(CC1)C(=O)OC2C3=NC=CN=C3C(=O)N2C4=NC=C(C=C4)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Gastrooesophageal reflux disease07.02.02.003--
Gastrointestinal disorder07.11.01.001---
Hallucination19.10.04.003--
Hallucination, visual19.10.04.007---
Hangover08.01.09.018---
Headache17.14.01.001--
Hostility19.05.01.003---
Hyperacusis04.02.02.001; 17.04.03.003---
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hypersensitivity10.01.03.003--
Hypersomnia17.15.01.001; 19.02.05.001--
Hypoaesthesia17.02.06.023; 23.03.03.081---
Hypotonia15.05.04.008; 17.05.02.002---
Hypoxia22.02.02.003--
Illusion19.10.05.006---
Increased appetite08.01.09.027; 14.03.01.003---
Injection site bruising08.02.03.042; 12.07.03.042; 23.03.11.015; 24.07.06.017---
Injection site pain08.02.03.010; 12.07.03.011---
Insomnia17.15.03.002; 19.02.01.002--
Intestinal obstruction07.13.01.002---
Irritability08.01.03.011; 19.04.02.013--
Jaundice01.06.04.004; 09.01.01.004; 23.03.03.030---
Joint stiffness15.01.02.003---
Joint swelling15.01.02.004---
Laboratory test abnormal13.18.01.001---
Lethargy08.01.01.008; 17.02.04.003; 19.04.04.004--
Libido decreased19.08.03.001; 21.03.02.005--
Loss of consciousness17.02.04.004---
Malaise08.01.01.003--
Mass08.03.05.003---
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene